Track PRLD and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Prelude Therapeutics Inc
175 Innovation Boulevard, Wilmington, DE, United States, 19805
IPO
2020
Employees
79
Industry
Biotechnology
Sector
Healthcare
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 20260+2
2
Analyst Ratings
3 analysts covering
Buy67%recommend buy
Buy
2
Hold
0
Sell
1